EIKO Lifesciences Intrinsic Value
EIKO Lifesciences intrinsic value. EIKO Lifesciences (EIKO) median intrinsic value is ₹43.43 from 9 valuation models (range ₹19–₹69), vs current price ₹47.57 — -8.7% downside (Trading Near Calculated Value), margin of safety -9.5%. Compare with EIKO fundamental valuation to assess whether the stock is under or overvalued.
EIKO Valuation Methods Summary — DCF, Graham Number & P/E
EIKO Lifesciences intrinsic value across 9 models vs current price ₹47.57 — upside/downside and value range per method. Read EIKO ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹44.64 | ₹35.71 - ₹53.57 | -6.2% | EPS: ₹3.72, Sector P/E: 12x |
| Book Value Method | asset | ₹50.00 | ₹45.00 - ₹55.00 | +5.1% | Book Value/Share: ₹50.00, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹43.43 | ₹39.09 - ₹47.77 | -8.7% | Revenue/Share: ₹54.29, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹34.29 | ₹30.86 - ₹37.72 | -27.9% | EBITDA: ₹8.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹19.03 | ₹15.22 - ₹22.84 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹23.81 | ₹21.43 - ₹26.19 | -49.9% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹30.65 | ₹27.59 - ₹33.72 | -35.6% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹68.57 | ₹61.71 - ₹75.43 | +44.1% | ROE: 11.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹64.69 | ₹58.22 - ₹71.16 | +36.0% | EPS: ₹3.72, BVPS: ₹50.00 |
EIKO Intrinsic Value vs Market Price — All Valuation Models
EIKO Lifesciences fair value range ₹19–₹69 vs current market price ₹47.57 across 9 valuation models. For current market price and key ratios, visit EIKO share price.
EIKO Intrinsic Value Analysis — Undervalued or Overvalued?
EIKO Lifesciences median intrinsic value ₹43.43, current price ₹47.57 — Trading Near Calculated Value by 8.7%, margin of safety -9.5%.
What is the intrinsic value of EIKO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of EIKO Lifesciences (EIKO) is ₹43.43 (median value). With the current market price of ₹47.57, this represents a -8.7% variance from our estimated fair value.
The valuation range spans from ₹19.03 to ₹68.57, indicating ₹19.03 - ₹68.57.
Is EIKO undervalued or overvalued?
Based on our multi-method analysis, EIKO Lifesciences (EIKO) appears to be trading near calculated value by approximately 8.7%.
EIKO Financial Health — Key Ratios vs Industry Benchmarks
EIKO Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
EIKO Cash Flow Quality — Operating & Free Cash Flow
EIKO Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹2 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹3 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2020 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2019 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |